Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026)
Revolution Medicines' (RVMD) quarterly Non-Current Deferred Tax Liability came in at $2.4 million in Q1 2026, little changed year-on-year from $2.4 million in Q1 2025, and little changed quarter-over-quarter from $2.4 million in Q4 2025.
Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Revolution Medicines' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.4 million, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability held at $2.4 million in Q1 2026 per RVMD's latest filing, from $2.4 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $7.4 million in Q1 2022 and bottomed at $2.4 million in Q4 2024.
- The 5-year median for Non-Current Deferred Tax Liability is $3.1 million (2023), against an average of $4.3 million.
- Across the five-year window, Non-Current Deferred Tax Liability changed 0.0% in 2022 and sank 55.82% in 2023, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $7.0 million in 2022, then tumbled by 55.66% to $3.1 million in 2023, then retreated by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
- Per Business Quant, the three latest RVMD Non-Current Deferred Tax Liability figures stand at $2.4 million (Q1 2026), $2.4 million (Q4 2025), and $2.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Dec 31, 2023 | 3.12 Mn |